PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
批准号:
7606126
负责人:
SHLOMO MELMED
金额:
$0.08万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-02-01 至 2007-11-30
关键词:
AdultComputer Retrieval of Information on Scientific Projects DatabaseDoseDrug KineticsFundingGrantInstitutionLabelMedical SurveillancePharmacodynamicsPhasePituitary NeoplasmsResearchResearch PersonnelResourcesSafetySourceTitrationsUnited States National Institutes of Healthdesigngrowth hormone deficiencyimmunogenicityr-hGH-M
中文摘要
这个子项目是许多利用
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
本研究是一项在成人发作生长激素缺乏症受试者中进行的1期、多中心、开放标签、阿尔布托品剂量滴定研究。 本研究旨在评价不同剂量rHA-rHGH皮下给药在成人型生长激素缺乏症受试者中的安全性、耐受性、免疫原性、药代动力学和药效学。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
This study is a Phase 1, multicenter, open-label, dose-titration of Albutropin in subjects with adult onset growth hormone deficiency. The study is designed to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of difference doses of subcutaneously administered rHA-rHGH in subjects with adult onset growth hormone deficiency.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)
-
批准号:10003845
-
项目类别:
-
资助金额:$46.78万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for GH action on epithelial cells
-
批准号:10578571
-
项目类别:
-
资助金额:$36.74万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for GH action on epithelial cells
-
批准号:9893867
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Treatment of pituitary Cushing disease with a selective CDK inhibitor, R-roscovit
-
批准号:8773516
-
项目类别:
-
资助金额:$23.44万
-
财政年份:2014
-
负责人:SHLOMO MELMED
-
依托单位:
Cedars-Sinai Biobank and Translational Research Core Facility (CS-BRCF)
-
批准号:7935157
-
项目类别:
-
资助金额:$955.29万
-
财政年份:2010
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7606124
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2007
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7376014
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2005
-
负责人:SHLOMO MELMED
-
依托单位:
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
-
批准号:7376016
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2005
-
负责人:SHLOMO MELMED
-
依托单位:
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
-
批准号:7206322
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2004
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7206320
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2004
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:7008190
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:6599784
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:7172931
-
项目类别:
-
资助金额:$30.68万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:6833420
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Pituitary Tumor Surveillance: Pathogenetic Correlation
-
批准号:7042064
-
项目类别:
-
资助金额:$1.41万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:6710585
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for Pituitary Tumorigenesis
-
批准号:7042061
-
项目类别:
-
资助金额:$1.41万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Information Technology for Human Subjects Protection
-
批准号:6591413
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2002
-
负责人:SHLOMO MELMED
-
依托单位:
Gordon Research Conference on Prolactin
-
批准号:6623298
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2002
-
负责人:SHLOMO MELMED
-
依托单位:
Gordon Research Conference on Prolactin
-
批准号:6464530
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2002
-
负责人:SHLOMO MELMED
-
依托单位: